Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 333

1.

Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JC.

Ther Drug Monit. 2019 Apr;41(2):253-254. doi: 10.1097/FTD.0000000000000597. No abstract available.

PMID:
30883521
2.

CRP-guided Antibiotic Treatment in acute exacerbations of COPD admitted to Hospital.

Prins HJ, Duijkers R, van der Valk P, Schoorl M, Daniels JMA, van der Werf TS, Boersma WG.

Eur Respir J. 2019 Mar 17. pii: 1802014. doi: 10.1183/13993003.02014-2018. [Epub ahead of print]

PMID:
30880285
3.

Random glucose sampling as screening tool for diabetes among disadvantaged tuberculosis patients residing in urban slums in India.

Gröschel MI, Luz CF, Batra S, Ahuja S, Batra S, Kranzer K, van der Werf TS.

ERJ Open Res. 2019 Mar 11;5(1). pii: 00025-2019. doi: 10.1183/23120541.00025-2019. eCollection 2019 Feb.

4.

Tuberculosis-related Malnutrition: Public Health Implications.

Ter Beek L, Alffenaar JC, Bolhuis MS, van der Werf TS, Akkerman OW.

J Infect Dis. 2019 Mar 5. pii: jiz091. doi: 10.1093/infdis/jiz091. [Epub ahead of print]

PMID:
30835281
5.

Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in MDR-TB patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02379-18. doi: 10.1128/AAC.02379-18. [Epub ahead of print]

PMID:
30782999
6.

Levofloxacin pharmacokinetics and pharmacodynamics and outcome in MDR-TB patients.

Ghimire S, Maharjan B, Jongedijk EM, Kosterink JGW, Ghimire GR, Touw DJ, van der Werf TS, Shrestha B, Alffenaar JC.

Eur Respir J. 2019 Jan 17. pii: 1802107. doi: 10.1183/13993003.02107-2018. [Epub ahead of print] No abstract available.

PMID:
30655280
7.

Posaconazole trough concentrations are not influenced by inflammation: A prospective study.

Märtson AG, Veringa A, Bakker M, van den Heuvel ER, Touw DJ, van der Werf TS, Span LFR, C Alffenaar JW.

Int J Antimicrob Agents. 2019 Mar;53(3):325-329. doi: 10.1016/j.ijantimicag.2019.01.006. Epub 2019 Jan 11.

8.

Different underlying mechanism might explain the absence of a significant difference in AUC of linezolid for different ABCB1 genotypes.

Bolhuis MS, Akkerman OW, Sturkenboom MGG, de Lange WCM, van der Werf TS, Touw DJ, Alffenaar JWC.

Ther Drug Monit. 2019 Jan 9. doi: 10.1097/FTD.0000000000000597. [Epub ahead of print] No abstract available.

PMID:
30633090
9.

The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.

Pranger AD, van der Werf TS, Kosterink JGW, Alffenaar JWC.

Drugs. 2019 Feb;79(2):161-171. doi: 10.1007/s40265-018-1043-y. Review.

10.

Treatment for Buruli ulcer: the long and winding road to antimicrobials-first.

Omansen TF, Stienstra Y, van der Werf TS.

Cochrane Database Syst Rev. 2018 Dec 17;12:ED000128. doi: 10.1002/14651858.ED000128. No abstract available.

PMID:
30556580
11.

Darunavir Population Pharmacokinetic Model Based on HIV Outpatient Data.

Daskapan A, Tran QTD, Cattaneo D, Gervasoni C, Resnati C, Stienstra Y, Bierman WFW, Kosterink JGW, van der Werf TS, Proost JH, Alffenaar JC, Touw DJ.

Ther Drug Monit. 2019 Feb;41(1):59-65. doi: 10.1097/FTD.0000000000000576.

12.

Evaluation of Carbapenems for Treatment of Multi- and Extensively Drug-Resistant Mycobacterium tuberculosis.

van Rijn SP, Zuur MA, Anthony R, Wilffert B, van Altena R, Akkerman OW, de Lange WCM, van der Werf TS, Kosterink JGW, Alffenaar JC.

Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01489-18. doi: 10.1128/AAC.01489-18. Print 2019 Feb.

PMID:
30455232
13.

A Systematic Review on the Effect of HIV Infection on the Pharmacokinetics of First-Line Tuberculosis Drugs.

Daskapan A, Idrus LR, Postma MJ, Wilffert B, Kosterink JGW, Stienstra Y, Touw DJ, Andersen AB, Bekker A, Denti P, Hemanth Kumar AK, Jeremiah K, Kwara A, McIlleron H, Meintjes G, van Oosterhout JJ, Ramachandran G, Rockwood N, Wilkinson RJ, van der Werf TS, Alffenaar JC.

Clin Pharmacokinet. 2018 Nov 8. doi: 10.1007/s40262-018-0716-8. [Epub ahead of print] Review.

14.

Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients.

van den Elsen SHJ, Sturkenboom MGG, Van't Boveneind-Vrubleuskaya N, Skrahina A, van der Werf TS, Heysell SK, Mpagama S, Migliori GB, Peloquin CA, Touw DJ, Alffenaar JC.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e01092-18. doi: 10.1128/AAC.01092-18. Print 2018 Dec.

PMID:
30373800
15.

Pathogen-based precision medicine for drug-resistant tuberculosis.

Gröschel MI, Walker TM, van der Werf TS, Lange C, Niemann S, Merker M.

PLoS Pathog. 2018 Oct 18;14(10):e1007297. doi: 10.1371/journal.ppat.1007297. eCollection 2018 Oct. No abstract available.

16.

Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC, Walsh K, Westenhouse J, Yew WW, Yim JJ, Zetola NM, Zignol M, Menzies D.

Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Review.

PMID:
30215381
17.

[Tuberculosis: from compulsory admission to compulsory treatment].

Drijver-Messelink MT, Kerstjens HAM, de Lange WCM, de Vries J, van der Werf TS, Akkerman OW.

Ned Tijdschr Geneeskd. 2018 Aug 3;162. pii: D2439. Dutch.

PMID:
30182637
18.

Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis.

Harausz EP, Garcia-Prats AJ, Law S, Schaaf HS, Kredo T, Seddon JA, Menzies D, Turkova A, Achar J, Amanullah F, Barry P, Becerra M, Chan ED, Chan PC, Ioana Chiotan D, Crossa A, Drobac PC, Fairlie L, Falzon D, Flood J, Gegia M, Hicks RM, Isaakidis P, Kadri SM, Kampmann B, Madhi SA, Marais E, Mariandyshev A, Méndez-Echevarría A, Moore BK, Nargiza P, Ozere I, Padayatchi N, Ur-Rehman S, Rybak N, Santiago-Garcia B, Shah NS, Sharma S, Shim TS, Skrahina A, Soriano-Arandes A, van den Boom M, van der Werf MJ, van der Werf TS, Williams B, Yablokova E, Yim JJ, Furin J, Hesseling AC; Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in MDR-TB.

PLoS Med. 2018 Jul 11;15(7):e1002591. doi: 10.1371/journal.pmed.1002591. eCollection 2018 Jul.

19.

Intermediate Susceptibility Dose-Dependent Breakpoints For High-Dose Rifampin, Isoniazid, and Pyrazinamide Treatment in Multidrug-Resistant Tuberculosis Programs.

Zuur MA, Pasipanodya JG, van Soolingen D, van der Werf TS, Gumbo T, Alffenaar JC.

Clin Infect Dis. 2018 Nov 13;67(11):1743-1749. doi: 10.1093/cid/ciy346.

PMID:
29697766
20.

Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial.

Wadagni AC, Barogui YT, Johnson RC, Sopoh GE, Affolabi D, van der Werf TS, de Zeeuw J, Kleinnijenhuis J, Stienstra Y.

Lancet Infect Dis. 2018 Jun;18(6):650-656. doi: 10.1016/S1473-3099(18)30160-9. Epub 2018 Apr 5.

PMID:
29605498
21.

Diagnostic Tests for Buruli Ulcer: Clinical Judgment Revisited.

van der Werf TS.

Clin Infect Dis. 2018 Aug 31;67(6):835-836. doi: 10.1093/cid/ciy203. No abstract available.

PMID:
29538643
22.

Pharmacokinetics of 2,000 Milligram Ertapenem in Tuberculosis Patients.

Zuur MA, Ghimire S, Bolhuis MS, Wessels AMA, van Altena R, de Lange WCM, Kosterink JGW, Touw DJ, van der Werf TS, Akkerman OW, Alffenaar JWC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02250-17. doi: 10.1128/AAC.02250-17. Print 2018 May.

23.

Correction: Variability and cost implications of three generations of the Roche LightCycler® 480.

Dullaert-de Boer M, Akkerman OW, Vermeer M, Hess DLJ, Kerstjens HAM, Anthony RM, van der Werf TS, van Soolingen D, van der Zanden AGM.

PLoS One. 2018 Feb 9;13(2):e0192946. doi: 10.1371/journal.pone.0192946. eCollection 2018.

24.

Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.

Akkerman OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, de Vries G, Bolhuis MS, Alffenaar JW, Frijlink HW, Smith G, Gajraj R, de Zwaan R, Hagedoorn P, Dedicoat M, van Soolingen D, van der Werf TS.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702490. doi: 10.1183/13993003.02490-2017. Print 2018 Mar. No abstract available.

25.

Variability and cost implications of three generations of the Roche LightCycler® 480.

Dullaert-de Boer M, Akkerman OW, Vermeer M, Hess DLJ, Kerstjens HAM, Anthony RM, van der Werf TS, van Soolingen D, van der Zanden AGM.

PLoS One. 2018 Jan 12;13(1):e0190847. doi: 10.1371/journal.pone.0190847. eCollection 2018. Erratum in: PLoS One. 2018 Feb 9;13(2):e0192946.

26.

Lack of penetration of amikacin into saliva of tuberculosis patients.

van den Elsen SHJ, Akkerman OW, Huisman JR, Touw DJ, van der Werf TS, Bolhuis MS, Alffenaar JC.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan. No abstract available.

PMID:
29326320
27.

In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin.

Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01724-17. doi: 10.1128/AAC.01724-17. Print 2018 Mar.

28.

Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis.

Ravensbergen SJ, Louka C, Lokate M, Bathoorn E, Pournaras S, van der Werf TS, de Lange WCM, Stienstra Y, Akkerman OW.

Am J Trop Med Hyg. 2018 Feb;98(2):376-378. doi: 10.4269/ajtmh.17-0544. Epub 2017 Dec 21.

29.

Risk factors contributing to a low darunavir plasma concentration.

Daskapan A, Stienstra Y, Kosterink JGW, Bierman WFW, van der Werf TS, Touw DJ, Alffenaar JC.

Br J Clin Pharmacol. 2018 Mar;84(3):456-461. doi: 10.1111/bcp.13464. Epub 2017 Dec 7.

30.

Methicillin Resistant Staphylococcus aureus Transmission in a Ghanaian Burn Unit: The Importance of Active Surveillance in Resource-Limited Settings.

Amissah NA, Buultjens AH, Ablordey A, van Dam L, Opoku-Ware A, Baines SL, Bulach D, Tetteh CS, Prah I, van der Werf TS, Friedrich AW, Seemann T, van Dijl JM, Stienstra Y, Stinear TP, Rossen JW.

Front Microbiol. 2017 Oct 6;8:1906. doi: 10.3389/fmicb.2017.01906. eCollection 2017.

31.

Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis.

Boonstra JM, van der Elst KC, Veringa A, Jongedijk EM, Brüggemann RJ, Koster RA, Kampinga GA, Kosterink JG, van der Werf TS, Zijlstra JG, Touw DJ, Alffenaar JWC.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01398-17. doi: 10.1128/AAC.01398-17. Print 2017 Dec.

32.

Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD.

Prins HJ, Duijkers R, Lutter R, Daniels JM, van der Valk P, Schoorl M, Kerstjens HA, van der Werf TS, Boersma WG.

Respir Med. 2017 Oct;131:118-124. doi: 10.1016/j.rmed.2017.07.064. Epub 2017 Aug 1.

PMID:
28947018
33.

Non-Steroidal Anti-inflammatory Drugs As Host-Directed Therapy for Tuberculosis: A Systematic Review.

Kroesen VM, Gröschel MI, Martinson N, Zumla A, Maeurer M, van der Werf TS, Vilaplana C.

Front Immunol. 2017 Jun 30;8:772. doi: 10.3389/fimmu.2017.00772. eCollection 2017. Review.

34.

Epidemiology of Staphylococcus aureus in a burn unit of a tertiary care center in Ghana.

Amissah NA, van Dam L, Ablordey A, Ampomah OW, Prah I, Tetteh CS, van der Werf TS, Friedrich AW, Rossen JW, van Dijl JM, Stienstra Y.

PLoS One. 2017 Jul 13;12(7):e0181072. doi: 10.1371/journal.pone.0181072. eCollection 2017.

35.

Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.

Daskapan A, Dijkema D, de Weerd DA, Bierman WFW, Kosterink JGW, van der Werf TS, Alffenaar JC, Stienstra Y.

Br J Clin Pharmacol. 2017 Oct;83(10):2325-2329. doi: 10.1111/bcp.13366. Epub 2017 Aug 1.

36.

Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis Patients.

Van't Boveneind-Vrubleuskaya N, Seuruk T, van Hateren K, van der Laan T, Kosterink JGW, van der Werf TS, van Soolingen D, van den Hof S, Skrahina A, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e00343-17. doi: 10.1128/AAC.00343-17. Print 2017 Aug.

37.

Virulence potential of Staphylococcus aureus isolates from Buruli ulcer patients.

Amissah NA, Chlebowicz MA, Ablordey A, Tetteh CS, Prah I, van der Werf TS, Friedrich AW, van Dijl JM, Stienstra Y, Rossen JW.

Int J Med Microbiol. 2017 Jun;307(4-5):223-232. doi: 10.1016/j.ijmm.2017.04.002. Epub 2017 Apr 19.

38.

Simple strategy to assess linezolid exposure in patients with multi-drug-resistant and extensively-drug-resistant tuberculosis.

Kamp J, Bolhuis MS, Tiberi S, Akkerman OW, Centis R, de Lange WC, Kosterink JG, van der Werf TS, Migliori GB, Alffenaar JC.

Int J Antimicrob Agents. 2017 Jun;49(6):688-694. doi: 10.1016/j.ijantimicag.2017.01.017. Epub 2017 Apr 4.

PMID:
28389352
39.

Yellow fever in a traveller returning from Suriname to the Netherlands, March 2017.

Wouthuyzen-Bakker M, Knoester M, van den Berg AP, GeurtsvanKessel CH, Koopmans MP, Van Leer-Buter C, Oude Velthuis B, Pas SD, Ruijs WL, Schmidt-Chanasit J, Vreden SG, van der Werf TS, Reusken CB, Bierman WF.

Euro Surveill. 2017 Mar 16;22(11). pii: 30488. doi: 10.2807/1560-7917.ES.2017.22.11.30488.

40.

Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.

Van Kampenhout E, Bolhuis MS, Alffenaar JC, Oswald LM, Kerstjens HA, de Lange WC, van der Werf TS, Akkerman OW.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601724. doi: 10.1183/13993003.01724-2016. Print 2017 Mar. No abstract available.

41.

Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.

Van der Paardt AL, Akkerman OW, Gualano G, Palmieri F, Davies Forsman L, Aleksa A, Tiberi S, de Lange WC, Bolhuis MS, Skrahina A, van Soolingen D, Kosterink JG, Migliori GB, van der Werf TS, Alffenaar JC.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601612. doi: 10.1183/13993003.01612-2016. Print 2017 Mar. No abstract available.

42.

Recombinant BCG Expressing ESX-1 of Mycobacterium marinum Combines Low Virulence with Cytosolic Immune Signaling and Improved TB Protection.

Gröschel MI, Sayes F, Shin SJ, Frigui W, Pawlik A, Orgeur M, Canetti R, Honoré N, Simeone R, van der Werf TS, Bitter W, Cho SN, Majlessi L, Brosch R.

Cell Rep. 2017 Mar 14;18(11):2752-2765. doi: 10.1016/j.celrep.2017.02.057.

43.

Neurological and functional recovery in tuberculosis patients with spinal cord injury in The Netherlands.

Wouda EMN, Stienstra Y, van der Werf TS, Kerstjens H, de Lange WCM, Coppes M, Kuijlen J, Tepper M, Akkerman OW.

NeuroRehabilitation. 2017;40(3):439-445. doi: 10.3233/NRE-161431.

PMID:
28222564
44.

Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.

van Rijn SP, Zuur MA, van Altena R, Akkerman OW, Proost JH, de Lange WC, Kerstjens HA, Touw DJ, van der Werf TS, Kosterink JG, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01783-16. doi: 10.1128/AAC.01783-16. Print 2017 Apr.

45.

Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis.

van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01400-16. doi: 10.1128/AAC.01400-16. Print 2017 Mar.

46.

Individualized treatment of multidrug-resistant tuberculosis using therapeutic drug monitoring.

Bolhuis MS, Akkerman OW, Sturkenboom MG, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S44-S45. doi: 10.1016/j.ijmyco.2016.07.003. Epub 2016 Aug 8.

47.

Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.

Velink A, Woolley RJ, Phillips RO, Abass KM, van der Werf TS, Agumah E, de Zeeuw J, Klis S, Stienstra Y.

PLoS Negl Trop Dis. 2016 Dec 29;10(12):e0005261. doi: 10.1371/journal.pntd.0005261. eCollection 2016 Dec.

48.

Bioavailability of voriconazole in hospitalised patients.

Veringa A, Geling S, Span LF, Vermeulen KM, Zijlstra JG, van der Werf TS, Kosterink JG, Alffenaar JC.

Int J Antimicrob Agents. 2017 Feb;49(2):243-246. doi: 10.1016/j.ijantimicag.2016.10.010. Epub 2016 Nov 23.

PMID:
28012684
49.

Therapeutic drug monitoring of first-line anti-tuberculosis drugs comprises more than C2h measurements.

Sturkenboom MG, Bolhuis MS, Akkerman OW, de Lange WC, van der Werf TS, Alffenaar JC.

Int J Tuberc Lung Dis. 2016 Dec;20(12):1695-1696. No abstract available.

PMID:
27931348
50.

Low Caspofungin Exposure in Patients in Intensive Care Units.

van der Elst KC, Veringa A, Zijlstra JG, Beishuizen A, Klont R, Brummelhuis-Visser P, Uges DR, Touw DJ, Kosterink JG, van der Werf TS, Alffenaar JC.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01582-16. doi: 10.1128/AAC.01582-16. Print 2017 Feb.

Supplemental Content

Loading ...
Support Center